Sanofi Ventures contributed to a series C round for Dice Molecules, which is advancing a potential psoriasis treatment.
US-based small molecule drug developer Dice Molecules closed an $80m series C round on Friday featuring Sanofi Ventures, the corporate venturing subsidiary of pharmaceutical firm Sanofi.
RA Capital Management led the round, which also attracted spinout-focused investment firm Osage University Partners and Alexandria Venture Investments, the venture capital arm of real estate investment trust Alexandria Real Estate Equities,
Eventide Asset Management, New Leaf Venture Partners, Soleus Capital, Driehaus Capital Management, Asymmetry Capital Management, Northpond Ventures, Sands Capital, Altitude Life Science…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
